Lincoln Park Capital Fund LLC

Major Investor Commits $30M To Psychedelics Funding

Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30 million (CA$41) of its common shares within a 36-month period.

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement For Up To $20M

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicag